がん研究のアーカイブ

  • ISSN: 2254-6081
  • ジャーナル h-index: 13
  • 雑誌引用スコア: 3.58
  • ジャーナルのインパクトファクター: 3.12
インデックス付き
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • Google スカラー
  • 秘密検索エンジン研究所
このページをシェアする

抽象的な

State of the Science in Radiation Oncology and Priorities for Clinical Trials Meeting Report from the European Organization for Research and Treatment of Cancer

Barley Jamish

New technologies and techniques in radiation medical specialty and imaging supply opportunities to reinforce the good thing about loco-regional treatments expand treatment to new patient populations like those with oligometastatic unwellness and reduce traditional tissue toxicity. Moreover, novel agents became obtainable which can be combined with actinotherapy, and identification of radiation-related biomarkers is studied to refine treatment prescriptions. Finally, the utilization of AI (AI) capabilities can also improve treatment quality assurance or the benefit with that radiation dosing is prescribed. All of those potential advances gift each opportunities and challenges for educational clinical researchers. Recently, the Organisation for analysis and Treatment of Cancer addressed these topics in an exceedingly meeting of multiple stakeholders from Europe and North America. the subsequent 5 themes radiobiology-based biomarkers, new technologies – significantly nucleon beam medical aid, combination general and actinotherapy, management of oligometastatic unwellness and AI opportunities in radiation medical specialty were mentioned in an exceedingly State of Science format to outline key controversies, nonreciprocal queries and propose run priorities for development.

Keywords

Cytoreductive surgery; Peritoneal metastases mitomycin C; Hyperthermia; Radical appendectomy

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません